The present invention includes a method of resolving gold from iodine using a multi-detector Spectral Computed Tomography (CT) scanner comprising: obtaining an image using the scanner of a subject provided a gold contrast agent; performing a Spectral CT material differentiation or imaging at 140 kVp using one or more scanner tubes; and calculating a DE ratio for ratio of gold, wherein the DE ratio is about 1.0.

Design and use of an administered drug in the form of a nanoparticle or molecule is described. In certain examples, the nanoparticle has a core and a shell surrounding the core. The core may be configured or designed to provide useful X-ray attenuating properties, gamma ray emission properties, magnetic properties, or therapeutic effects. In certain aspects, the nanoparticle or molecule is sized so as to either distribute from or remain in the blood pool, while still being eliminated by the kidneys.

Design and use of an administered drug in the form of a nanoparticle or molecule is described. In certain examples, the nanoparticle has a core and a shell surrounding the core. The core may be configured or designed to provide useful X-ray attenuating properties, gamma ray emission properties, magnetic properties, or therapeutic effects. In certain aspects, the nanoparticle or molecule is sized so as to either distribute from or remain in the blood pool, while still being eliminated by the kidneys.

Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

A method is for imaging an examination region of an object to be examined, the examination region including a first contrast medium and a second contrast medium different from the first contrast medium. In an embodiment, the method includes acquisition and generation. In the acquisition, first projection scan data is acquired in an examination region with a first energy range and second projection scan data, different from the first projection scan data, is acquired with a second energy range different from the first energy range. In the generation, a first image is generated based upon the first projection scan data and the second projection scan data and the first image has furthermore only isolated first information of the first contrast medium, only isolated second information of the second contrast medium, or isolated first information of the first contrast medium together with isolated second information of the second contrast medium.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

Materials and methods for synthesizing magnetic core/gold shell nanoparticles and magneto-plasmonic nanostars are provided. Formulations comprising nanoparticles optionally bound to or co-loaded with a therapeutic agent encapsulated within liposomes are provided. A method for treating diseases (e.g., brain diseases) in a subject by administering to the subject a formulation comprising the nanoparticle formulation is also provided. Further, a method is provided for imaging a target site of a subject following the administering of the nanoparticle formulations.

The disclosure provides improvements of resolution and contrast in the field of x-ray imaging by using a line emitting, quasi-monochromatic x-ray source for x-ray fluorescence computed tomography. A particular type of x-ray source suitable for this is a line emitting liquid-jet-anode x-ray source. X-ray fluorescence is obtained using nanoparticles, preferably coated nanoparticles with a metallic core. The x-ray radiation from the x-ray source is shaped and filtered using energy dispersive optics before being delivered to the nanoparticles.

Radiopaque bismuth particles and methods of making and using the radiopaque bismuth particles are disclosed. The radiopaque bismuth particles include an elemental bismuth core and an outer coating comprising one or more coating agents. Disclosed radiopaque bismuth particles are suitable for use in surgical sponges and plastic objects.

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.